Checkpoint inhibitors in melanoma and early phase development in solid tumors: What's the future?

Paolo A. Ascierto, Grant A. McArthur

Research output: Contribution to journalComment/debate

19 Citations (Scopus)

Abstract

Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in combination with other cancer treatments. In addition, recent research has shown that immune-based therapy can be used as adjuvant therapy, that outcomes may be influenced by dose, and that clinical activity is observed in patients with brain metastases. Despite our increased understanding of these agents, there are still several important questions that need to be answered. These include strategies to overcome primary and acquired resistance, the influence of mutational status on treatment outcomes, the optimal duration of treatment, and the need to identify novel combination regimens that offer increased anti-tumour potency and/or reduced toxicity. Here we review recent developments in these areas, with particular focus on new data reported at the 2017 ASCO Annual Meeting.

Original languageEnglish
Article number173
JournalJournal of Translational Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - Aug 8 2017

Fingerprint

Tumors
Melanoma
Histology
Oncology
Toxicity
Brain
Neoplasms
Ligands
Therapeutics
Immunotherapy
Neoplasm Metastasis
Safety
Research

Keywords

  • Anti-PD-1
  • Anti-PD-L1
  • Combination therapy
  • Immunotherapy
  • Melanoma

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Checkpoint inhibitors in melanoma and early phase development in solid tumors : What's the future? / Ascierto, Paolo A.; McArthur, Grant A.

In: Journal of Translational Medicine, Vol. 15, No. 1, 173, 08.08.2017.

Research output: Contribution to journalComment/debate

@article{28afd276ed944f40b3b0ce709c823db2,
title = "Checkpoint inhibitors in melanoma and early phase development in solid tumors: What's the future?",
abstract = "Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in combination with other cancer treatments. In addition, recent research has shown that immune-based therapy can be used as adjuvant therapy, that outcomes may be influenced by dose, and that clinical activity is observed in patients with brain metastases. Despite our increased understanding of these agents, there are still several important questions that need to be answered. These include strategies to overcome primary and acquired resistance, the influence of mutational status on treatment outcomes, the optimal duration of treatment, and the need to identify novel combination regimens that offer increased anti-tumour potency and/or reduced toxicity. Here we review recent developments in these areas, with particular focus on new data reported at the 2017 ASCO Annual Meeting.",
keywords = "Anti-PD-1, Anti-PD-L1, Combination therapy, Immunotherapy, Melanoma",
author = "Ascierto, {Paolo A.} and McArthur, {Grant A.}",
year = "2017",
month = "8",
day = "8",
doi = "10.1186/s12967-017-1278-5",
language = "English",
volume = "15",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Checkpoint inhibitors in melanoma and early phase development in solid tumors

T2 - What's the future?

AU - Ascierto, Paolo A.

AU - McArthur, Grant A.

PY - 2017/8/8

Y1 - 2017/8/8

N2 - Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in combination with other cancer treatments. In addition, recent research has shown that immune-based therapy can be used as adjuvant therapy, that outcomes may be influenced by dose, and that clinical activity is observed in patients with brain metastases. Despite our increased understanding of these agents, there are still several important questions that need to be answered. These include strategies to overcome primary and acquired resistance, the influence of mutational status on treatment outcomes, the optimal duration of treatment, and the need to identify novel combination regimens that offer increased anti-tumour potency and/or reduced toxicity. Here we review recent developments in these areas, with particular focus on new data reported at the 2017 ASCO Annual Meeting.

AB - Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in combination with other cancer treatments. In addition, recent research has shown that immune-based therapy can be used as adjuvant therapy, that outcomes may be influenced by dose, and that clinical activity is observed in patients with brain metastases. Despite our increased understanding of these agents, there are still several important questions that need to be answered. These include strategies to overcome primary and acquired resistance, the influence of mutational status on treatment outcomes, the optimal duration of treatment, and the need to identify novel combination regimens that offer increased anti-tumour potency and/or reduced toxicity. Here we review recent developments in these areas, with particular focus on new data reported at the 2017 ASCO Annual Meeting.

KW - Anti-PD-1

KW - Anti-PD-L1

KW - Combination therapy

KW - Immunotherapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=85027143031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027143031&partnerID=8YFLogxK

U2 - 10.1186/s12967-017-1278-5

DO - 10.1186/s12967-017-1278-5

M3 - Comment/debate

AN - SCOPUS:85027143031

VL - 15

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 173

ER -